Influencer claims, fact-checked
Common objections to the peptide field, lined up against what the published evidence actually shows. Each response surfaces the part the critic gets right alongside the part that does not survive contact with the underlying literature.
8 responses live as of latest review.
01·BPC-157
BPC-157 will give you cancer because it's pro-angiogenic
Pro-angiogenic activity in rodent models is real, but the cancer-risk leap conflates mechanism with clinical outcome — there is no human evidence that BPC-157 administration causes or accelerates cancer, and the entire BPC-157 human safety record is small enough that a population signal could not yet be detected either way.
Read the full response
02
Compounded peptides are unsafe
Sourcing quality is real and consequential, and the gap between regulatory-grade pharmacy compounding and unregulated 'research chemical' supply is wider than most readers realize — but the objection collapses the two and treats every non-branded peptide as equivalent risk.
Read the full response
03·Ipamorelin
Ipamorelin is just steroids with extra steps
Anabolic steroids and Ipamorelin are pharmacologically distinct in three load-bearing ways — the hormone they raise, how it ages out, and what they do to the rest of the endocrine system — and conflating the two trades clarity for false equivalence.
Read the full response
04
It's all just placebo because the studies are so small
Sample size matters and small trials produce wider confidence intervals around the true effect, but the objection misunderstands what placebo-controlled means and applies a critique appropriate for a thin literature uniformly across a corpus that is not uniformly thin.
Read the full response
05
Peptides will mess with your hormones long-term
Long-term endocrine effects are a real concern for the GH-axis and metabolic peptide classes — IGF-1 elevation, GLP-1 receptor adaptation, glucagon-axis activation — but they are class-specific, not a property of 'peptides' as a category, and the long-term human data exists for some peptides on this list and is genuinely absent for others.
Read the full response
06·Selank
Selank is a Russian psychotropic with no Western evidence
The Russian clinical literature exists and is substantial; what is missing is independent Western RCT replication — and the right framing is parallel evidence bases that have not yet converged, not an absence of evidence.
Read the full response
07·Semaglutide
Semaglutide makes you lose muscle
Lean-mass loss during semaglutide-induced weight loss is real and measurable, but the magnitude varies widely across studies, much of it tracks what any equivalent caloric deficit produces, and the published mitigation (adequate protein plus resistance training) consistently moves the lean-mass-to-fat-loss ratio in the right direction.
Read the full response
08
There's no human research on most of these peptides
The claim is partially true and the part that is true matters, but the corpus splits cleanly into peptides with substantial human RCT evidence (Tesamorelin, Semaglutide, Tirzepatide, PT-141) and peptides where the human data is genuinely thin — and the page on each peptide says which is which.
Read the full response